We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
+17.79%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$141M
AUM Growth
-$9.65M
Cap. Flow
+$2.6M
Cap. Flow %
1.84%
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
IPSC icon
Century Therapeutics
IPSC
+$25.6M

Top Sells

Rank Stock Value
1
GLUE icon
Monte Rosa Therapeutics
GLUE
+$23M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GLUE icon
1
Monte Rosa Therapeutics
GLUE
$1.32B
$52.3M 37%
3,180,780
-1,201,907
-27% -$23M
IPSC icon
2
Century Therapeutics
IPSC
$346M
$27.5M 19.44%
+12,166,109
New +$25.6M
LENZ
3
LENZ Therapeutics
LENZ
$162M
$24.3M 17.19%
2,656,888
– –
JBIO
4
Jade Biosciences
JBIO
$1.34B
$21.4M 15.16%
1,525,820
– –
CTNM
5
Contineum Therapeutics
CTNM
$573M
$7.09M 5.01%
542,628
– –
CRSP icon
6
CRISPR Therapeutics
CRSP
$5.01B
$7.08M 5.01%
148,831
– –
SKYE icon
7
Skye Bioscience
SKYE
$20M
$1.23M 0.87%
2,007,704
– –
TPST icon
8
Tempest Therapeutics
TPST
$14.6M
$442K 0.31%
269,772
– –

Similar funds

POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
RB
Renasant Bank Tupelo, Mississippi $141M AUM 16.9% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
CFGW
Chancellor Financial Group WB Wilkes-Barre, Pennsylvania $141M AUM 23.22% 1-Year Est. Return
CL
CRCM LP San Francisco, California $141M AUM 153.09% 1-Year Est. Return

Versant Venture Management's Q1 2026 Portfolio in Review

As of Q1 2026, Versant Venture Management held 8 positions worth $141M, down 6.4% from $151M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management's Q1 2026 filing shows 1 new and 1 reduced positions. Its largest new stake was Century Therapeutics: 12,166,109 shares worth $27.5M. The largest sale was Monte Rosa Therapeutics, an estimated $23M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Versant Venture Management's largest Q1 2026 buy was Century Therapeutics: 12,166,109 shares worth $27.5M.
  • Versant Venture Management's biggest Q1 2026 reduction was Monte Rosa Therapeutics, cutting an estimated $23M.
  • Versant Venture Management's ten largest holdings make up 100% of its $141M portfolio in Q1 2026.
  • Versant Venture Management opened 1 new position and closed 0 in Q1 2026.
  • Versant Venture Management's portfolio value fell 6.4% quarter-over-quarter to $141M.

Based on Versant Venture Management's 13F filing for Q1 2026, filed 5 May 2026.